Artículos relacionados
[Translated article] Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis
diciembre 27, 2022
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 113. Núm. 7. (Julio - Agosto 2022)
Interleukin 31 (IL-31) is a neurocytokine that stimulates sensory neurons involved in pruritus. It contributes to skin barrier inflammation, dysfunction, and remodeling. As the immune and nervous systems are interrelated, IL-31 has a key role […]
[Translated article] Update on Chronic Prurigo
diciembre 27, 2022
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 113. Núm. 6. (Junio 2022)
Chronic prurigo is itself a common condition, but it can also occur secondary to a large number of diseases. Management is challenging as historically chronic prurigo has been poorly defined and very few treatments are […]
Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience
marzo 18, 2024
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 115. Núm. 2. (Febrero 2024)
Background Dupilumab is a new targeted therapy for severe atopic dermatitis (AD) with limited real-world evidence. Objective Explore our experience with dupilumab for AD in clinical practice at a tertiary care center. Material and method […]